Novartis Announced The Us Food And Drug Administration (Fda) Has Granted Accelerated Approval For Kymriah (Tisagenlecleucel) For The Treatment Of Adult Patients With Relapsed Or Refractory (R/R) Follicular Lymphoma (Fl) After Two Or More Lines Of Systemic Therapy.In Accordance With The Accelerated Approval Programme, Continued Approval For This Indication May Be Contingent Upon Verification And Description Of Clinical Benefit In Confirmatory Trial(S). Kymriah Is Now Fda Approved In Three Indications And Remains The Only Car-T Cell Therapy Approved In Both Adult And Paediatric Settings."We Are Proud Of Today'S Fda Approval Of A Third Indication For Kymriah. We Hope This Treatment Option That Has The Potential For Long-Lasting Results May Help Break The Unrelenting Cycle Of Treatment For Patients With Follicular Lymphoma,
